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ABSTRACT
Objective: Antibiotics are mostly prescribed empirically to decrease health-care costs. This has led to the misuse of antibiotics thereby making them 
inefficient in the treatment of infections. The aim of this study was to determine the appropriate, cost-effective drug for the empirical therapy in 
microbial infections.
Methods: A prospective observational study was conducted for a period of 6 months. Cost-effectiveness ratio (CER) of these antibiotics prescribed 
was calculated to determine the cost-effective drugs for the common microorganisms and common infections.
Results: In a population of 205 patients, 54.6% were treated based on antibiotic sensitivity pattern whereas 45.3% were treated empirically. In 
known microbial infections, the prevailing microorganism was extended-spectrum beta-lactamase (ESBL) producing Escherichia-coli (14.3%), 
Staphylococcus aureus (10.6%), Pseudomonas aeruginosa (9.8%), Klebsiella pneumonia (9.8%), and K. pneumoniae ESBL (6.81%). Based on the CER, 
the most cost-effective drugs for these organisms were found to be ciprofloxacin, clindamycin, ofloxacin, levofloxacin, and amikacin, respectively. In 
unknown microbial infection (empirical treatment), Diabetic Foot Infection (DFT) (25.8%), respiratory tract infection (RTI) (23.6%), and urinary 
tract infection (UTI) (16.1%) were the most common infections. The most cost-effective drugs for these infections were clindamycin, levofloxacin, and 
azithromycin, respectively. The predominant microorganism in DFT was found to be S. aureus (71%), in UTI was found to be E. coli ESBL (52%), and 
in RTI were found to be P. aeruginosa (42.4%) and K. pneumonia (32.3%).
Conclusion: Appropriate empirical antibiotic treatment is associated with a lower medical cost and a better success rate in patients with microbial 
infections.
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INTRODUCTION
Infection is the invasion and multiplication of disease-causing microbes 
into a human’s body tissue and the reaction of the host tissue to these 
microbes and the toxins they produce. Infection is a common occurrence 
that has required patients to seek medical care and for antibiotics to 
be prescribed [1]. Antibiotics have made a significant contribution 
to improving the health of patients with microbial infections [2]. The 
unnecessary prescribing of antibiotics have led to increased cost of 
care by increasing resistance, drug cost, and cost for laboratory test [3]. 
Hence, while prescribing the antibiotic, important considerations 
like the accurate diagnosis of infection, understanding the difference 
between empirical and definitive therapy, cost-effective oral agents for 
the shortest duration should be included.
Antibiotic resistance is a major worldwide problem, and its implication 
on public health is becoming overwhelming [4-6]. Culture test helps to 
identify the causative organism and the effective drugs against these 
organisms can be determined by susceptibility tests. Cost is one among 
the various factors to be considered [7]. Hence, the antibiotics are 
mostly prescribed empirically to decrease the health-care cost.
A vast majority of infections are treated empirically, therefore, the 
choice of an antimicrobial agent should be adjusted by local sensitivity 
pattern as the rising prevalence of multidrug- resistant infections 
cause more complexity in the empirical treatment of these infections. 
Awareness of local antimicrobial resistance trends among microbial 
isolates is important for the appropriate use of antibiotics and for the 
evidence-based recommendations in the empirical antibiotic treatment 
of infections [8]. Therefore, pharmacoeconomic decision analysis is 
a way to convey the relative value of beneficial treatments, and the 
choice must be directed to obtain maximum benefit to the society. The 
alternative with the lowest cost to effectiveness ratio (CER) is preferred 
for the microbial infections. This study determines the appropriate, 
cost-effective antibiotics for the empirical therapy for the infections 
based on the sensitivity pattern of prevailing microorganisms. 
There is need to improve our antibiotic prescribing practices and to 
strengthen research to identify cost-effective strategies for controlling 
resistance. This could ameliorate the care of the individual patient 
tremendously [9].
METHODS
A prospective observational study was conducted over a period of 6 
months from March 2016 to August 2016 in a multispecialty tertiary 
care hospital in Coimbatore, India. The study was approved to be 
conducted in PSG Institute of Medical Science and Research by the 
Institutional Human Ethics Committee (IHEC) (ref no: 16/092 dated on 
14/03/2016). Patients receiving only one antibiotic who were treated 
either empirically or with culture sensitivity tests were included in the 
study. During this period 205 patients were enrolled in the study based 
on inclusion and exclusion criteria. Non-hospitalized, patients with 
incomplete and insufficient data/record and who received antibiotic as 
prophylaxis were excluded in the study. Data were collected using data 
collection form from the sources; laboratory tests and patient case file. 
The patients enrolled in the study were reviewed for 2 weeks. The total 
cost of each antibiotic was calculated based on the unit cost of drug, 
frequency and the number of days of administration.
Total cost=Unit cost×frequency×number of days.
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Study subjects were grouped based on the culture test; known 
microorganisms (sensitivity pattern therapy group) and unknown 
microorganisms (empirical therapy group). The cost-effectiveness 





Total cost of antibiotic INR
CER
Outcome success rate %
The outcome was calculated as the percentage of successful treatments. 
CER was calculated for antibiotics prescribed in both the groups. From 
this analysis, the drug with the least CER was the most cost-effective 
drug of choice.
RESULTS
During the study period, 205 subjects met the criteria. Out of these 205 
patients, 66.83% were male patients, and 33.17% were female patients. 
40% of these patients were hospitalized for 6–10 days.
The study population was divided into two groups based on the culture 
test: Culture test with known microorganisms (sensitivity pattern 
therapy group) and culture test with the unknown microorganism 
(empirical therapy group). Table 1 summarizes the antibiotics mostly 
prescribed for the common microorganisms and infections.
Cost-effectiveness analysis of antibiotics for most commonly known 
organisms and unknown microorganisms were done, and a decision 
tree was prepared based on CER. In Escherichia coli extended-spectrum 
beta-lactamase (ESBL) infection, the most common cost-effective 
drug was found to be amikacin (CER=29.03) followed by ceftriaxone 
(CER=44.92) as shown in Table 2.
Likewise, the cost-effectiveness analysis was performed for the other 
known microorganism as reported in Table 3.
Similarly, a cost-effectiveness analysis was performed for microbial 
infection with unknown microorganism and reported in Table 4.
The predominant microorganism in diabetic foot infection (DFT) 
was found to be Staphylococcus aureus (71%), E. coli ESBL (52%) in 
urinary tract infection (UTI) then Pseudomonas aeruginosa (42.4%), 
and Klebsiella pneumonia (32.3%) in respiratory tract infection 
(RTI).
Comparison of antibiotics of preference suggested in both known and 
unknown microbial infections showed that clindamycin was the best 
drug of choice for DFI and infections caused by S. aureus. It is also 
evident from the study that levofloxacin is the best drug of choice for 
RTI and infections caused by K. pneumonia, which is one of the common 
causative organisms for RTI. P. aeruginosa was also a predominant 
isolate in RTI, and the best drug of choice was ciprofloxacin. In UTI, the 
most common causative agent was E. coli ESBL, and nitrofurantoin was 
found to be the best alternative Table 5 represents the above data.
DISCUSSION
In this study, demographic characteristics of the participants involved 
in the study were categorized based on gender and age distribution. A 
study conducted by Thomas et al. in South India indicated the majority 
of the patients were male 68.5%, the age distribution of these patients 
was between 41 and 60 years (43.6%). Their study also showed that 
cephalosporins (73.0%) are the most prescribed class of antibiotics 
followed by fluoroquinolones (53.9%) which are in accordance with 
our study [10]. As per the study conducted by Dominick et al., it was 
reported that amikacin, piperacillin+tazobactam, cefepime, and 
nitrofurantoin were the most preferred drug in E. coli and K. pneumonia 
ESBL infection to avoid resistance to beta-lactams (meropenem 
and imipenem) which were expensive and could be used for more 
severe infections instead [11]. As stated by Rayner and Munckhof in 
their study conducted in Poland, penicillinase-resistant penicillins 
(flucloxacillin and dicloxacillin) were the best drugs in the treatment of 
severe infections of methicillin-sensitive S. aureus and acute infections, 
the first generation cephalosporins, and clindamycin could be used [4].
A study conducted by Suleiman et al. revealed Ciprofloxacin to be the 
most cost-effective treatment for sensitive isolates of P. aeruginosa when 
compared to ceftazidime and gentamicin. In resistant isolates, amikacin 
was dominantly more cost-effective when compared to meropenem and 
imipenem [6]. As per Canadian study conducted by Chow et al., showed 
clindamycin dominated other drugs such as cephalexin, cloxacillin, 
levofloxacin, and amoxicillin+clavulanate with the lowest CER in the 
treatment of DFT [12]. Radji et al. conducted a study in Indonesia found 
that the most common infecting microorganisms on pus culture to be 
Table 1: Antibiotics mostly prescribed for the common microorganisms and infections
Groups Organisms/infections (%) Antibiotics prescribed (%)
Sensitivity pattern therapy group (known microorganisms) E. coli ESBL (14.39) Amikacin (22)
Ceftriaxone (17)
Cefoperazone+sulbactam (17)
S. aureus (10.6) Amoxicillin+clavulanate (59)
Piperacillin+tazobatam (24)
Clindamycin (19)
P. aeruginosa (9.84) Piperacillin+tazobatam (36)
Clindamycin (23)
Ofloxacin (23)
K. pneumoniae (9.84) Levofloxacin (31)
Ceftriaxone (31)
Piperacillin-tazobactam (23)
K. pneumoniae ESBL (6.81) Piperacillin+tazobactam (36)
Meropenem (22)
Amikacin (21)
Empirical therapy group (infections) DFI (25.80) Amoxicillin+clavulanate (44.18)
Clindamycin (25.58)
RTI (23.65) Ceftriaxone (41.17)
Azithromycin (17.64)
Levofloxacin (14.75)
UTI (16.12) Cefoperazone+sulbactam (21.05)
Piperacillin+tazobactam (20.1)
E-coli: Escherichia coli, ESBL: Extended-spectrum beta-lactamase, S. aureus: Staphylococcus aureus, P. aeruginosa: Pseudomonas aeruginosa, K. pneumonia: Klebsiella 
pneumonia, DFI: Diabetic foot infection, RTI: Respiratory tract infection, UTI: Urinary tract infection
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Staphylococcus spp. 47.5%, Pseudomonas spp. 16.9%, and E. coli 10.2%, 
Streptococcus spp. 8.5%. Overall, 37.2% of DFI was caused by a single 
organism, and 62.8% had polymicrobial infections [13]. Commonly 
administered antibiotics were ceftriaxone 40.0%, ciprofloxacin 11.4%, 
and meropenem 8.6%. The empiric antibiotic regimen of clindamycin 
and ciprofloxacin covered 85% of S. aureus and 78% of Gram-negative 
species of DFI in a study conducted by de Vries et al. in Netherlands [14].
An Egyptian study by Harwan et al. reported that respiratory 
fluoroquinolone such as Levofloxacin should be regarded as a first line 
antimicrobials in admitted and outpatients due to their association with 
increased clinical response, faster resolutions, greater improvement of signs 
and symptoms and shorter hospital length of stay [15]. According to a study 
conducted in Nigeria by Egbe et al., Klebsiella pneumoniae was reported to 
be the predominant isolate fluoroquinolones, beta-lactams, and Gentamicin 
showed moderate to high activity [16]. Varotto, Maria found the four most 
frequent isolates in RTI to be P. aeruginosa 24%, Streptococcus pyogenes 
18%, Staphylococcus spp. 17%, and Klebsiella spp. 8%.
IDSA guidelines state that the first line treatment for UTI is 
nitrofurantoin and fluoroquinolones. Dudas et al. reported that 80% of 
UTI was caused by E. coli in Northern California. Most patients were 
treated empirically using beta-lactams, nitrofurantoin, fosfomycin 
tromethamine, fluoroquinolones, and trimethoprim eradicate Gram-
negative flora, hence, provide best long-term cures [17]. In the USA, 
Bouza et al. found E. coli to be the main etiological agent of UTI [18]. 
A study in Turkey on the evaluation of empirical treatment by Yüksel 
et al. reported that the most common causative agent was E. coli 87%, 
Klebsiella 10%. Nitrofurantoin was the most active agent against E. coli 
followed by amikacin and ceftriaxone [19].
This study had some limitations. First, it was conducted for a short 
period (6 months), therefore, the sensitivity pattern could not be 
thoroughly assessed. Second, the cost focused on only antibiotics; other 
medical expenses were not included. Finally, the data were analyzed 
from one of the tertiary care hospitals in Southern India.
CONCLUSION
Appropriate empirical antibiotic treatment is associated with a lower 
medical cost and a better success rate in patients with microbial 
infections. Efforts to improve the appropriateness of empirical 
antibiotic treatment should be dictated by the benefit inherent 
inappropriate treatment. The choice of antimicrobial agent should 
be adjusted by local sensitivity pattern as there might be geographic 
differences in sensitivity patterns. In addition, prudent use of available 
antibiotic drugs, improved methods of prediction, and rapid detection 
of resistance is clearly needed.
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